StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) KPIs and segments

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.65−0.11 (-6.25%)

Close on Nov 17, 2026Market cap $995.04KP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Silexion Therapeutics's business

Silexion Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
FY2025
FY2024
FY2023
China($M)
0.01-0.19-0.31
Cayman Islands($M)
-2.57-4.160
Israel($M)
-9.35-12.2-4.77

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-03-17.

See a number that looks wrong?